膝下动脉血运重建使用紫杉醇涂层器械的长期结局:倾向性评分匹配队列分析
该研究基于德国第二大保险基金2010至2018年膝下动脉首次血运重建患者数据,采用倾向性评分匹配比较紫杉醇涂层与未涂层器械。匹配后6 568例患者中,紫杉醇涂层器械与五年全因死亡(HR 0.84)、截肢或死亡(HR 0.87)及心血管事件或死亡(HR 0.86)风险降低相关。
要点
- 膝下动脉使用紫杉醇涂层器械与五年全因死亡风险降低相关(HR 0.84)。
- 紫杉醇涂层器械组截肢或死亡风险降低(HR 0.87)。
- 心血管事件或死亡风险亦降低(HR 0.86)。
核心结论
- 在倾向性评分匹配队列中,膝下动脉使用紫杉醇涂层器械相比未涂层器械,五年全因死亡、截肢或死亡及心血管事件或死亡风险均降低。
研究设计与样本
- 仅纳入首次暴露于紫杉醇涂层器械的患者,按球囊 vs. 支架分层,并使用倾向性评分将紫杉醇涂层器械患者与未涂层器械患者匹配。
- 共纳入14 738例患者(平均年龄77.6岁,女性43.6%),其中6 568例匹配患者进入分析。
- 采用Kaplan-Meier法和Cox回归评估结局。
主要发现
- 研究期间紫杉醇涂层器械使用率增加(2010年6% vs. 2018年31%,p < .001)。
- 五年随访期间共发生2 611例(39.8%)死亡。
- 倾向性评分匹配Cox模型显示,紫杉醇相关五年全因死亡风险降低(HR 0.84,95%CI 0.78-0.91)。
- 截肢或死亡风险降低(HR 0.87,95%CI 0.81-0.94)。
- 心血管事件或死亡风险降低(HR 0.86,95%CI 0.80-0.92)。
临床怎么用
- 对于慢性肢体威胁性缺血患者,膝下动脉血运重建时可考虑使用紫杉醇涂层器械以降低远期死亡、截肢及心血管事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular revascularisation has become a standard approach for below knee lesions and paclitaxel coated devices have been widely used in patients with chronic limb threatening ischaemia. A recent meta-analysis reported higher mortality in paclitaxel coated devices compared with uncoated devices in femoropopliteal lesions. This study aimed to determine long term outcomes in below the knee interventions using paclitaxel coated devices in routine vascular care using a large and contemporary cohort. METHODS: A large cohort was created using all inclusive health insurance claims data of patients covered by the second largest insurance fund in Germany. The cohort included patients with index revascularisation of arteries below the knee performed from 1 January 2010, to 31 December 2018. Only patients with first paclitaxel coated device exposure were included. The study cohort was stratified into balloon vs. stent treatment and patients with paclitaxel coated devices were matched with uncoated devices using propensity score. Outcomes were evaluated using the Kaplan-Meier method and Cox regression. RESULTS: There were 14 738 patients (mean age 77.6 years, 43.6% female) and 6 568 matched patients included in the study. Increasing use of paclitaxel coated devices was observed during the study period (6% in 2010 vs. 31% in 2018, p < .001), and a total of 2 611 (39.8%) deaths occurred within five years of follow up. In the propensity score matched Cox model, a paclitaxel related reduction of five year mortality (hazards ratio, HR 0.84, 95% confidence interval, CI 0.78-0.91), amputation or death (HR 0.87, 95% CI 0.81-0.94), and cardiovascular event or death (HR 0.86, 95% CI 0.80-0.92) were observed. CONCLUSION: In this propensity score matched cohort, reduced long term all cause mortality, reduced rates of amputation or death and cardiovascular event or death were observed at five years after the use of paclitaxel coated devices when compared with uncoated devices for the treatment of chronic limb threatening ischaemia.
引用
- Heidemann F, Peters F, Kuchenbecker J, et al. Long Term Outcomes After Revascularisations Below the Knee with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis. Eur J Vasc Endovasc Surg. 2020. PMID: 32807674. doi:10.1016/j.ejvs.2020.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。